BETWEEN DRUG FREE SPORT NEW ZEALAND

Applicant

AND HINEWAI HAUSMAN

Respondent

PROVISIONAL SUSPENSION ORDER 23 June 2023

Parties Hayden Tapper, Drug Free Sport New Zealand

Kate Hursthouse, counsel for Applicant

Hinewai Hausman, Respondent

Nick Elsmore, counsel for Respondent

Chair Warwick Smith (Acting Chair)

Registrar Helen Gould

1. Hinewai Hausman (Mrs Hausman) is a New Zealand power lifter who was sanctioned

with a four year period of ineligibility commencing on 13 April 2019 for admitting the

presence of clenbuterol following an adverse analytical finding and proceedings

brought to the Tribunal Drug Free Sport New Zealand (DFSNZ).

2. Rule 10.14.1 of the Sports Anti-doping Rules (SADR) provides that DFSNZ can test

an athlete at any time during the period of ineligibility. Accordingly, Mrs Hausman was

tested by DFSNZ on 4 April 2023, nine days before her period of ineligibility was due

to expire. That test showed the presence of prohibited non-specified substances:

Drostanolone, Norandrostenedione, Oxandrolone and Metenolone.

3. On 20 June 2023, DFSNZ filed an Application for Provisional Suspension alleging

breaches of 2022 SADR 2.1 and 2.2.

4. On 23 June 2023, Counsel for the Respondent, Mr Elsmore, confirmed by email that

Mrs Hausman accepts the Provisional Suspension.

5. There is no need for a provisional suspension hearing.

6. Accordingly, the Tribunal Acting Chair is satisfied that there is no substantive reason

why provisional suspension should not be imposed.

Orders

7. The Tribunal orders that provisional suspension of Mrs Hausman will have effect from

23 June 2023, prohibiting her participation of any kind in any event or activity

organised, sanctioned or authorised by any sporting organisation that is a signatory to

the SADR.

8. A copy of this Provisional Suspension Order will be sent to the parties but otherwise

will remain confidential until publication of the final decision on the alleged Anti-Doping

Rule Violations. All other process steps under the SADR should similarly remain

confidential.

Dated: 23 June 2023

Warwick Smith Acting Chair

Dan